A Phase 3 clinical trial evaluating deucrictibant, a compound studied in relation to bradykinin-mediated angioedema, is now recruiting as of September 21, 2026. The study, registered as NCT07266805, is titled "Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency."
The trial is designed to assess an extended-release tablet form of deucrictibant for prophylaxis and a soft capsule form for on-demand treatment. It targets adults diagnosed with acquired angioedema due to C1 inhibitor deficiency. According to the registry listing, the study status is currently recruiting participants.
No results have been posted for this trial at this time. The listing does not provide efficacy or safety outcome data, and none should be inferred from the trial's current recruiting status. Additional details regarding trial design, eligibility criteria, and enrollment can be found on the official ClinicalTrials.gov listing.
Bradykinin is classified as an unapproved compound used in research settings. Readers interested in background on bradykinin's role in this research area can consult the compound overview for further context.